Navigation Links
Clarient to Commercialize Novel Breast Cancer Profile
Date:1/9/2008

t

Clarient combines innovative technologies with world class expertise to assess and characterize cancer. Clarient's mission is to provide the services, resources and critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and drug development services available both onsite and over the web. Clarient is a Safeguard Scientifics, Inc. partner company. http://www.clarientinc.com

About Safeguard

Safeguard Scientifics, Inc. (NYSE: SFE), a holding company, builds value in growth-stage technology and life sciences businesses. Safeguard provides growth capital as well as a range of strategic, operating and management resources to our partner companies. Safeguard participates in growth buyout financings, including corporate spin-outs and management buyouts, expansion financings, industry consolidations and early-stage financings. http://www.safeguard.com

The statements herein regarding Clarient, Inc. contain forward-looking statements that involve risks and uncertainty. Future events and the Company's actual results could differ materially from the results reflected in these forward-looking statements.
'/>"/>

SOURCE Clarient
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
2. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
3. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
4. Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia
5. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
6. New Drug Application for Tolvaptan, Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
7. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
8. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
9. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
10. First European Patient Treated in CABERNET Trial With Novel Treatment for Wet AMD
11. DOE JGI plumbs termite guts to yield novel enzymes for better biofuel production

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... , SAN MATEO, Calif., Nov. 24 /PRNewswire... biopharmaceutical company focused on developing a..., announced today that Anthony DiTonno, President ...nt at the 21st Annual Piper Jaffray Health Care Co... York Palace Hotel in New York, New York. ,, M...
(Date:11/24/2009)... The FBI recently approved th...tories participating in or generating DNA records ... Madison, WI USA (PRWEB) -- The FBI rec...ystem for use by laboratories participating in, o...ex System (NDIS). NDIS currently contains more tha...
(Date:11/24/2009)... , DUBLIN, November 24 /PRNewswire-First...e global specialty biopharmaceutical company, toda...opean Medicines Agency for,velaglucerase alfa, the...nt,for the treatment of Type 1 Gaucher disease. Th...erase alfa that has been submitted, with previous,...
(Date:11/24/2009)... , BOZEN, Italy, November 24 /PRNewswi... formed a new Canadian joint venture with a group ...o-based company will operate under the,name Health...nd support,Health Robotics, i.v. Room of the Futur...t offerings i.v.STATION(TM), i.v.SOFT(TM), and OMM...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 3
...e nation,s top-10 GPOs(1), IRVINE, Calif., Jan. 2...ead-Through Motion and Low Perfusion pulse,oximetr...lier agreement,with HealthTrust Purchasing Group (...ies, including acute care hospitals, ambulatory su...practices, with an annual,purchasing volume of mor...
...surement of Women,s Ovarian ...ductive Specialists (GRS),today announced it will ...the Repromedix Plan Ahead(TM) test, an innovative ...s egg supply by combining multiple factors,includi...Inhibin B, and,FSH. The window of opportunity for ...
...t renin inhibitor with the diuretic hydroc...ow combination of Tekturna and HCTZ resulted in si...ompared to either drug alone - Many treated patie... medicines - single-tablet combinations simplify ...f pills patients take, EAST HANOVER, N.J., Jan. 2...
Other Biology Technology:Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group 2Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group 3Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group 4Georgia Reproductive Specialists is First in Southeast to Offer Pioneering Test of Women's Biological Clock 2Georgia Reproductive Specialists is First in Southeast to Offer Pioneering Test of Women's Biological Clock 3Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 2Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 3Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 4Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 5
(Date:11/25/2009)...eptember 11, firefighters, police officers and amb... the World Trade Center complex. They battled to s...ed for survivors, tackled fires and evacuated as m...d an estimated 17,000 people. And making their job...ns: frightened workers and their relatives jammed ...
(Date:11/25/2009)... JOLLA, CAWhen you eat may be just as vital to you... Salk Institute for Biological Studies. Their expe... waning of thousands of genes in the liverthe body...food intake and not by the body,s circadian clock ...me determines the activity of a large number of ge...
(Date:11/24/2009)...ts that keep weakened and flabby arteries from col...months, those stents are no longer needed -- once ...sary. Previously, doctors had no choice but to lea...l Aviv University,s Department of Biomedical Engin...atform that carries drugs where they,re needed, th...
Breaking Biology News(10 mins):Magic box for mission impossible 2Magic box for mission impossible 3Feeding the clock 2Feeding the clock 3A coating for life 2MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results 53457 1MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results 53457 2MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results 53457 3MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results 53457 4MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results 53457 5MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results 53457 6MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results 53457 7Locum Leaders Taps Hospitalist as Chief Medical Officer 3B Strengthens Leadership in Hospital Medicine Recruitment and Job Placement 53452 1Locum Leaders Taps Hospitalist as Chief Medical Officer 3B Strengthens Leadership in Hospital Medicine Recruitment and Job Placement 53452 2Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program 4811 1Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program 4811 2Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program 4811 3Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program 4811 4
...MIT researchers have developed a technique to enco... a step that could help realize the therapeutic po...n many tissues in the body, are precursor cells fo...nd in the bone marrow develop into blood cells, bo...stem cells develop into brain tissue. , Those s...
...Researchers at Mount Sinai School of Medicine have...apture the movement of the microdomains of leukocy...ted areas on the surface of the cells in which rec...ell activation. Using digital multi-channel videom...od cell subsets and their forming microdomains in ...
...DNA testing is transforming health care and medici...of an individual,s genetic makeup. Any patient wan... genome, would drop their jaw at the sight of the ... charged for every human or mammalian-sized genome...ional Human Genome Research Institute (NHGRI), sci...
Other Biology News:MIT bioengineer advances survival, promise of adult stem cells 2MIT bioengineer advances survival, promise of adult stem cells 3New imaging technique tracks traffic patterns of white blood cells 2Faster, low cost sequencing technologies needed to drive era of personalized medicine 2Faster, low cost sequencing technologies needed to drive era of personalized medicine 3
Tramadol ELISA Kit, Single from Bio-Quant Inc.
...h Registered OLAW Assured AAALAC Accredited All Pr...ed Technicians Documentation GLP Process for All... CRP is your one stop shopping point for all your ...oject consultation, free peptide sequence recommen...
Dengue Virus IgM ELISA Kit, Single from Bio-Quant Inc.
THC ELISA Kit, Single from Bio-Quant Inc.
Biology Products: